Research article summary (published 29 Apr 2008):

[Pharmacogenetic contribution to individualized treatment. Severe adverse effects can be avoided]

(Farmakogenetik bidrar till individanpassad behandling. Allvarliga läkemedelsbiverkningar kan undvikas.)

Full Abstract

No abstract is available for this article. See 'Journal and Publication Information' further down the page for details that may assist you in locating this article in electronic or hard copy media. The 'Related articles' section also further down the page, where available, may show links to abstracts of articles covering similar topics.

Author information

Author/s: Eliasson, Erik (E);

Affiliation: Klinisk farmakologi, institutionen för laboratoriemedicin, Karolinska institutet. erik.eliasson(-atsign-)ki.se

Journal and publication information

Publication Type: Journal Article

Journal: Läkartidningen (Lakartidningen), published in Sweden. (Language: swe)

Reference: -2008 May 28-Jun 3; vol 105 (issue 22) : pp 1644-5

Dates: Created 2008/07/01; Completed 2008/07/02;

PMID: 18590003, status: MEDLINE (last retrieval date: 2/18/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Dideoxynucleosides - administration & dosage; adverse effects Drug Hypersensitivity - etiology; genetics; immunology HLA-B Antigens - genetics Humans

Pharmaceutical Preparations - administration & dosage; adverse effects Pharmacogenetics Risk Factors Safety

Associated Chemicals: Dideoxynucleosides (0) ; HLA-B Antigens (0) ; HLA-B*5701 antigen, human (0) ; Pharmaceutical Preparations (0) ; abacavir (0)

Related articles

These are the highest related articles currently in the database:

• Pharmacogenetics of hypersensitivity to abacavir: from PGx hypothesis to confirmation to clinical utility. 9 Mar 2008
• Abacavir hypersensitivity reaction predicted by genetic test. 24 Mar 2004
• High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. 30 Mar 2008
• Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet? 24 May 2006
• PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events. 30 Mar 2008
• Human leukocyte antigens and drug hypersensitivity. 30 Jul 2007
• Pharmacogenetic information derived from analysis of HLA alleles. 30 Jan 2008
• Pharmacogenomic biomarkers for prediction of severe adverse drug reactions. 5 Feb 2008
• The pharmacogenetics of antiretroviral therapy: a review of studies to date. 30 May 2004
• HLA-B*5701 screening for susceptibility to abacavir hypersensitivity. 20 Feb 2007

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.